The aim of the present phase II randomized trial ( Groupe Franais de Pneumo-Cancrologie 0501 ) was to compare , in patients with progressive small-cell lung cancer after first-line platinum-based chemotherapy , oral multidrug chemotherapy ( lomustine , cyclophosphamide , etoposide ) and intravenous therapy with cyclophosphamide , doxorubicin , and vincristine ( CAV ) in terms of efficacy and tolerance .